Free Trial

Upstream Bio Q3 2024 Earnings Report

Upstream Bio logo
$16.21 -0.40 (-2.41%)
(As of 12/20/2024 05:16 PM ET)

Upstream Bio EPS Results

Actual EPS
-$6.96
Consensus EPS
-$0.58
Beat/Miss
Missed by -$6.38
One Year Ago EPS
N/A

Upstream Bio Revenue Results

Actual Revenue
$0.61 million
Expected Revenue
$0.83 million
Beat/Miss
Missed by -$220.00 thousand
YoY Revenue Growth
N/A

Upstream Bio Announcement Details

Quarter
Q3 2024
Time
N/A

Conference Call Resources

Trump’s Sending THIS Crypto Higher on Purpose (Ad)

Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin…

YES, I WANT THE #1 CRYPTO NOW

Upstream Bio Earnings Headlines

Upstream Bio Appoints Allison Ambrose as General Counsel
Upstream Bio to join Russell 2000 index
Trump’s Sending THIS Crypto Higher on Purpose
Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin…
Upstream Bio Announces Addition to Russell 2000® Index
See More Upstream Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Upstream Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Upstream Bio and other key companies, straight to your email.

About Upstream Bio

Upstream Bio (NASDAQ:UPB), a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

View Upstream Bio Profile

More Earnings Resources from MarketBeat

Upcoming Earnings